semaglutide oral ACC 2025: Reduces Cardiovascular Events by 14% at 4 Years Article » PBD

Keep Your Brain Active Mental exercise strengthens neural connections

[1] It represents a novel class of medication as the first dual incretin receptor agonist, activating both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors

A study indicated that tirzepatide ameliorates high glucose-induced damage to nerve cells (Lin et al., 2023)

GLP-1 1(2.5mg) 7,000 7,700 1(5.0mg) 12,000 13,200 GLP-1 GLP-1 GLP-1 GLP-1 GLP- GLP-1 01. GLP-1 02. 03. GLP-1 GLP-1 BMI 3 2GIPGLP-1-1GIPGLP-1 2GIPGLP-1GLP-1 1 12.5mg2.5mg45mg15 mg4 GLP-197FDAGLP-11 11 0.611.2mg11.8mg 1.8mg GLP-1 GLP-1 111 1() 3~4 0.25mg40.5mg 40.5mg1.0mg 34 GLP-1 11 GLP-1 GLP-1 GLP-1 Q 1 A 1 Q A GLP-112122 Q A Q A 40 Q A GLP-12 92(BMI)27 Q A GLP-112122 Q A GLP-111 Q 1 A GLP-11180.630 Q A GLP-1 Q A FDA GLP-1

While competitors like semaglutide target only GLP-1 receptors, and tirzepatide hits both GLP-1 and GIP pathways, Retatrutide activates all three metabolically significant receptors: GLP-1, GIP, and glucagon